A checklist of best practices for mid-life products a few years after launch to help companies with growing oncology portfolios determine not only to see if there’s hidden vitality still left in their aging brands.
A checklist of best practices for mid-life products a few years after launch to help companies with growing oncology portfolios determine not only to see if there’s hidden vitality still left in their aging brands.
Sabina Heinz and Elizabeth Baynton look at how the continued absence of approved products affecting the management of NASH patients.
Why the time is right for P&T committees to incorporate real-world data and ‘real-world science’ into their product assessments.
Its use, new data shows, could boost the economic benefit profile of more “common” drugs-and better inform HTA and payer decision-making.
Exploring the critical go-to strategies for biopharma C-suite executives in navigating organizational disruption and the impact of global change and volatility on their employees and business.
Small- and medium-sized pharmas should revisit their pharmacovigilance strategies and adopt smarter end-to-end solutions to keep pace with increased volumes and rapidly changing regulatory requirements, writes Siva Thiagarajan.
Companies need to find compelling ways to present facts, rather than slick but insubstantial promotions.
Obtaining patient perspectives during open-label extension trials.
Obtaining patient perspectives during open-label extension trials.
The opportunities and challenges surrounding patient centricity and patient-centric trials in China.
The opportunities and challenges surrounding patient centricity and patient-centric trials in China.
The opportunities and challenges surrounding patient centricity and patient-centric trials in China.
The opportunities and challenges surrounding patient centricity and patient-centric trials in China.
The opportunities and challenges surrounding patient centricity and patient-centric trials in China.
More signs of alignment between startups, pharma, and payers.
How R&D organizations can leverage FDA’s final guidance on pre-approval information exchange (PIE) to engage with payers prior to approval and launch.
Melonie Warfel discusses the challenges organizations are facing when it comes to revenue management and looks at the key areas to optimize.
While culture may "eat" strategy, shared understanding creates both culture and strategy, write Steve Figman and Sean Robertson.
How pharma companies can bolster their quality management programs to meet FDA’s evolving compliance requirements.
Global content management needs are mounting among life sciences organizations, as they expand their market coverage and grapple with multiplying regulatory workloads. Monica Vytiskova asks if can intelligent automation offer a solution.
If telehealth is here to stay, how is the industry adjusting?
The importance of KOIs in tapping into today’s market mindset.
The importance of KOIs in tapping into today’s market mindset.
At last week’s 4th annual Prix Galien Forum hosted by the Alexandria Center in New York, industry leaders gathered to discuss trends and developments that shape the intersection between science and policy.
A 2019 study reveals further marginal decline in the pharma industry's reputation. Sven Klingemann suggests some "recovery solutions".
Coexisting with the DSCSA may hinder new legislative efforts.